NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. November 10, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news